[A Patient with Recurrent Invasive Thymoma Obtaining Long-Term Survival by Chemotherapy with Amrubicin Alone as the Third Treatment].

The patient was a 68-year-old woman. She was diagnosed with invasive thymoma 12years prior and underwent chemoradiotherapy( adriamycin, cisplatin, vincristine, and cyclophosphamide: ADOC)plus radiation exposure(62G y). After 11 years, the disease relapsed. Carboplatin plus paclitaxel(CP)therapy as a second-line therapy was ineffective, leading to enlargement of the primary tumor and the development of pleurisy. The third-line treatment with a single dose of amrubicin resulted in good disease control. There were no serious adverse events, and the drug tolerance was good. The patient has undergone 21courses of this treatment as of the time of this report and continues to maintain complete response(CR). No chemotherapy regimen as more than a second-line therapy demonstrated efficacy against recurrent thymoma. Amrubicin monotherapy may be an effective treatment option that may result in long-term survival with minor side effects.